Indications: growth retardation

Description:

1. For growth retardation caused by lack or deficiency of endogenous growth hormone.

2. The fusion molecule can reversibly combine with albumin, and has both long-term and sustained-release effects; The fusion molecule has low activity when binding with albumin in vivo, and maintains the activity of natural molecules after dissociation to achieve PK characteristics similar to natural molecules; The half-life of the fusion molecule is equivalent to that of HSA fusion or Fc fusion.

3. The molecular design of this project is innovative. At present, no drugs with similar design amount at home and abroad have entered the application stage, and are expected to become the first in class variety.